We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic's Mazor Buyout Creates a New Spine Surgery Major
Read MoreHide Full Article
Medtronic plc (MDT - Free Report) has finally completed its September-announced acquisition of Mazor Robotics. A successful integration of Mazor business will strengthen the company’s position in the growing robotic spine surgery space. Per Medtronic, this buyout ranks among the largest orthopedic deals closed in 2018.
Financial Terms of the Transaction
Shareholders of Mazor Robotics will receive $58.50 per American Depository Share or $29.25 per ordinary share in cash for an approximate total of $1.64 billion. The entire value of the transaction was $1.7 billion or $1.3 billion net of Medtronic`s existing stake in Mazor operations and cash acquired. Both companies’ boards have unanimously approved this deal.
Details of the Deal
Medtronic’s acquisition of the Israel-based robotic surgical guidance systems company Mazor Robotics is aligned with its strategic focus on growth in the field of robotics spine surgery.
Mazor Robotics' proprietary core platform technology including the Mazor X Robotic Guidance System and the Renaissance Surgical-Guidance System are transforming spinal surgery from freehand procedures into a more accurate, modern guided procedure. The buyout is expected to combine Medtronic's market-leading spine implants, navigation and intra-operative imaging technology with the acquired company's robotic-assisted surgery (RAS) systems.
With this takeover, Medtronic expects to offer a fully-integrated procedural solution for surgical planning, execution and confirmation. The company is also likely to further utilize Mazor Robotics' legacy of innovation in surgical robotics with the company’s site and team based in Israel.
Market Potential in Spine Space
Per a Mordor Intelligence report, the global market for Spinal Surgery Devices is estimated to reach worth $16.6 billion by 2021 at a 5% CAGR from 2016 onward. Taking such abundant prospects into account, we believe, the company’s latest development is a strategic fit.
Share Price Performance
Over the past three months, shares of Medtronic have outperformed its industry. The stock has lost 5.6%, narrower than the industry’s 13.6% decline.
Zacks Rank & Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) , Surmodics, Inc. (SRDX - Free Report) and Veeva Systems (VEEV - Free Report) .
Integer Holdings has an earnings growth rate of 31.2% for the first quarter of 2019 and a Zacks Rank #2 (Buy).
Surmodics’ long-term earnings growth rate is projected at 10%. The stock presently carries a Zacks Rank of 2.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Medtronic's Mazor Buyout Creates a New Spine Surgery Major
Medtronic plc (MDT - Free Report) has finally completed its September-announced acquisition of Mazor Robotics. A successful integration of Mazor business will strengthen the company’s position in the growing robotic spine surgery space. Per Medtronic, this buyout ranks among the largest orthopedic deals closed in 2018.
Financial Terms of the Transaction
Shareholders of Mazor Robotics will receive $58.50 per American Depository Share or $29.25 per ordinary share in cash for an approximate total of $1.64 billion. The entire value of the transaction was $1.7 billion or $1.3 billion net of Medtronic`s existing stake in Mazor operations and cash acquired. Both companies’ boards have unanimously approved this deal.
Details of the Deal
Medtronic’s acquisition of the Israel-based robotic surgical guidance systems company Mazor Robotics is aligned with its strategic focus on growth in the field of robotics spine surgery.
Mazor Robotics' proprietary core platform technology including the Mazor X Robotic Guidance System and the Renaissance Surgical-Guidance System are transforming spinal surgery from freehand procedures into a more accurate, modern guided procedure. The buyout is expected to combine Medtronic's market-leading spine implants, navigation and intra-operative imaging technology with the acquired company's robotic-assisted surgery (RAS) systems.
With this takeover, Medtronic expects to offer a fully-integrated procedural solution for surgical planning, execution and confirmation. The company is also likely to further utilize Mazor Robotics' legacy of innovation in surgical robotics with the company’s site and team based in Israel.
Market Potential in Spine Space
Per a Mordor Intelligence report, the global market for Spinal Surgery Devices is estimated to reach worth $16.6 billion by 2021 at a 5% CAGR from 2016 onward. Taking such abundant prospects into account, we believe, the company’s latest development is a strategic fit.
Share Price Performance
Over the past three months, shares of Medtronic have outperformed its industry. The stock has lost 5.6%, narrower than the industry’s 13.6% decline.
Zacks Rank & Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) , Surmodics, Inc. (SRDX - Free Report) and Veeva Systems (VEEV - Free Report) .
Integer Holdings has an earnings growth rate of 31.2% for the first quarter of 2019 and a Zacks Rank #2 (Buy).
Surmodics’ long-term earnings growth rate is projected at 10%. The stock presently carries a Zacks Rank of 2.
Veeva Systems’ long-term earnings growth rate is estimated at 19.5%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>